📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
BIL Vyapar Limited Schedules 8th Committee of Creditors Meeting for April 22, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 8th meeting of its Committee of Creditors (CoC) to be held on April 22, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing restructuring process to address the company's debt obligations. Investors should remain aware that the company's management is currently overseen by a Resolution Professional.
Key Highlights
8th meeting of the Committee of Creditors (CoC) scheduled for April 22, 2026
Company is currently under the Corporate Insolvency Resolution Process (CIRP)
Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR)
👀 What to Watch
Investors should exercise extreme caution as equity value is frequently diluted or eliminated during insolvency proceedings. Monitor the outcome of the CoC meeting for updates on potential resolution plans or liquidation risks.
Biocon Receives Health Canada Approval for Denosumab Biosimilars Bosaya and Vevzuo
Biocon has secured Health Canada approval for Bosaya and Vevzuo, biosimilars to the blockbuster drugs Prolia and Xgeva respectively. These approvals target a significant market in Canada, potentially benefiting over 2 million adults with osteoporosis and hundreds of patients with bone metastasis. The products are approved in standard dosages: Bosaya as a 60 mg/mL prefilled syringe and Vevzuo as a 120 mg/1.7 mL vial. This milestone expands Biocon's global biosimilar portfolio, which now includes 12 commercialized products and a pipeline of over 20 assets.
Key Highlights
Health Canada granted Notice of Compliance (NOC) for Bosaya (Prolia biosimilar) and Vevzuo (Xgeva biosimilar).
Targets a Canadian market of 2 million+ adults with osteoporosis and hundreds with bone metastasis annually.
Bosaya approved as 60 mg/mL prefilled syringe; Vevzuo approved as 120 mg/1.7 mL single-dose vial.
Biocon now has 12 commercialized biosimilar products and a robust pipeline of 20+ additional biosimilar assets.
👀 What to Watch
Investors should view this as a significant regulatory win that strengthens Biocon's position in the high-margin advanced markets. Monitor the commercial launch timeline and market share capture in Canada to gauge the impact on the Biologics segment revenue.
OnMobile Signs 3-Year Strategic Supply Agreement with Flipkart for Gaming Hardware Distribution
OnMobile Global Limited has entered into a three-year wholesale supply agreement with Flipkart India Private Limited, effective April 20, 2026. This partnership aims to distribute OnMobile's upcoming gaming hardware and digital services ecosystem across Flipkart's extensive e-commerce platform. The deal provides OnMobile with significant reach into the domestic gaming consumer segment through one of India's largest retail channels. Financial consideration will be determined per purchase order, making the immediate revenue impact dependent on order volumes.
Key Highlights
3-year wholesale supply agreement signed with Flipkart India Private Limited on April 20, 2026
Focuses on the distribution of gaming hardware and associated digital services in the domestic market
Strategic move to utilize Flipkart's reach for upcoming product launches and brand discoverability
Consideration is variable, to be decided based on individual purchase orders
👀 What to Watch
Investors should track the launch of the gaming hardware and monitor quarterly revenue growth from the digital services segment to assess the partnership's success.
Aditya Birla Money Appoints Amit Lahoti as Head of Equity Research
Aditya Birla Money Limited has appointed Mr. Amit Lahoti as the Head of Equity Research and a Senior Management Personnel, effective April 17, 2026. Mr. Lahoti brings over 15 years of specialized experience in the Metals and Mining sectors, having previously held significant roles at Emkay Global and Citigroup. This appointment is intended to strengthen the firm's core research capabilities and enhance investor engagement. The decision follows a recommendation from the Nomination and Remuneration Committee and was approved by the Board of Directors.
Key Highlights
Appointment of Mr. Amit Lahoti as Head of Equity Research effective April 17, 2026
Mr. Lahoti brings 15+ years of experience in global and Indian Metals & Mining sectors
Previous professional tenure includes leadership roles at Emkay Global and Citigroup
Designated as a Senior Management Personnel within the Core Management Team
👀 What to Watch
Investors should view this as a positive step toward strengthening the company's research-led advisory services. Monitor if this leadership addition leads to improved market visibility and client acquisition for the brokerage business.
Aditya Birla Money Q4 PAT Surges 255% YoY to ₹18.74 Cr; FY26 Revenue at ₹468.6 Cr
Aditya Birla Money reported a robust Q4 FY26 with Profit After Tax (PAT) jumping 255% YoY to ₹18.74 crore, driven by strong growth in the broking and wholesale debt market segments. Quarterly revenue from operations grew 30.5% YoY to ₹129.80 crore. While the quarterly performance was stellar, the full-year FY26 PAT saw a decline to ₹54.72 crore from ₹74.19 crore in FY25, largely due to higher finance costs and a one-time statutory impact of ₹3.13 crore related to new labour codes. The company's net worth strengthened to ₹300.25 crore as of March 31, 2026.
Key Highlights
Q4 FY26 PAT rose 255% YoY to ₹18.74 crore compared to ₹5.28 crore in the same quarter last year.
Quarterly Revenue from Operations increased 30.5% YoY to ₹129.80 crore from ₹99.46 crore.
Broking segment revenue for Q4 FY26 grew to ₹98.81 crore, up from ₹78.08 crore YoY.
Full-year FY26 PAT stood at ₹54.72 crore, impacted by a ₹3.13 crore exceptional item for new labour code compliance.
Debt-to-Equity ratio improved slightly to 7.18 as of March 2026 compared to 7.41 in March 2025.
👀 What to Watch
The strong quarterly momentum in the broking business indicates significant operational leverage and market share gains. Investors should watch for the sustainability of these quarterly margins in FY27 to see if they can offset the rising finance costs observed over the full year.
Bigbloc Construction Subsidiary Starts Trial Production at Umargaon Chemicals Plant
Bigbloc Construction Limited's wholly-owned subsidiary, Bigbloc Building Elements Private Limited, has successfully commenced trial production at its new Umargaon facility. This state-of-the-art plant is dedicated to construction chemicals, representing a strategic diversification of the company's product portfolio. The move aligns with the group's long-term strategy to expand its footprint in the construction materials sector. Investors should view this as a key step toward operationalizing new revenue streams.
Key Highlights
Wholly owned subsidiary Bigbloc Building Elements Private Limited begins trial production at Umargaon.
The new facility focuses on the construction chemicals segment, diversifying from traditional AAC blocks.
Strategic expansion aimed at reinforcing the Group’s position in the construction materials space.
The plant is described as a state-of-the-art facility incorporating modern innovation.
👀 What to Watch
Investors should monitor the timeline for the transition from trial production to full-scale commercial operations. This expansion into construction chemicals could potentially improve margins and provide a competitive edge in the building materials market.
Rubicon Research Acquires 85% Stake in Arinna Lifesciences for INR 175.92 Crores
Rubicon Research has announced the acquisition of an 85% equity stake in Arinna Lifesciences, marking its entry into the Indian domestic CNS formulations market. The transaction values Arinna at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores for the majority stake. Arinna is a specialist in Central Nervous System (CNS) therapies with over 60 brands and a network of 4,000+ prescribers. For the nine months ended December 2025, Arinna reported a provisional revenue of INR 56.7 Crores and an EBITDA of INR 9.5 Crores.
Key Highlights
Acquisition of 85% equity ownership in Arinna Lifesciences for a consideration of INR 175.92 Crores.
Arinna reported 9M FY26 provisional revenue of INR 56.7 Crores and EBITDA of INR 9.5 Crores.
The deal values Arinna at an Enterprise Value of INR 200 Crores on a cash and debt-free basis.
Strategic entry into the Indian CNS market with access to 60+ brands and 4,000+ prescribers.
Rubicon aims to leverage its R&D playbook which scaled its US revenues 32x between FY15 and FY25.
👀 What to Watch
Investors should look favorably on this acquisition as it diversifies Rubicon's revenue stream into the high-growth Indian domestic market. Monitor the successful integration of Arinna's distribution network with Rubicon's specialty product pipeline.
Triveni Turbine Merges South African Subsidiaries with Combined Turnover of Rs 169 Cr
Triveni Turbine has successfully merged its two South African step-down subsidiaries, TSE Engineering and Triveni Turbines Africa, effective April 1, 2026. The merger consolidates operations that had a combined FY25 turnover of approximately Rs 169 crore, with TTAPL contributing Rs 119 crore and TSE contributing Rs 50 crore. This internal restructuring is designed to simplify the group's corporate structure and enhance operational efficiencies in the African market. As both entities were 100% owned, there is no change in the parent company's shareholding pattern or cash outflow.
Key Highlights
TSE Engineering (Pty) Ltd merged into Triveni Turbines Africa (Pty) Ltd to consolidate South African operations.
The combined FY25 turnover of the two merged subsidiaries is Rs 169 crore (approx. ZAR 366 million).
The merger is effective from April 1, 2026, following approval from the South African CIPC.
Strategic rationale includes simplified governance, streamlined reporting, and enhanced administrative efficiency.
👀 What to Watch
No immediate action is required as this is a routine internal reorganization. Investors should monitor the company's international segment for potential margin improvements resulting from these operational efficiencies.
Rubicon Research to Acquire 85% Stake in Arinna Lifesciences for INR 175.92 Crores
Rubicon Research Limited has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences, an Ahmedabad-based branded pharmaceutical marketing firm. The acquisition is valued at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores in cash. Arinna specializes in the CNS and neuro-psychiatric therapeutic segments and reported a turnover of INR 71.5 Crores for FY25. This strategic move is intended to provide Rubicon with a domestic sales and distribution network to launch its specialty products and drug-device combinations in India.
Key Highlights
Acquisition of 85% equity stake in Arinna Lifesciences for approximately INR 175.92 Crores.
Target company Arinna reported a turnover of INR 71.50 Crores in FY25, up from INR 60.06 Crores in FY23.
The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt-free basis.
Strategic focus on the CNS (Central Nervous System) segment, leveraging Rubicon's IP and Arinna's distribution network.
The acquisition is expected to be completed within one month from the date of signing.
👀 What to Watch
This acquisition is a positive development as it provides Rubicon with a ready-made domestic platform to commercialize its CNS pipeline. Investors should monitor the integration and how this domestic presence impacts the company's overall margin profile.
BIL Vyapar Limited Schedules 7th Committee of Creditors Meeting for April 13, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 7th meeting of its Committee of Creditors (CoC) scheduled for April 13, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in determining the future of the company, including potential resolution plans or liquidation. As the company is under CIRP, the management is currently overseen by a Resolution Professional, and the powers of the Board of Directors remain suspended.
Key Highlights
7th meeting of the Committee of Creditors (CoC) to be held on April 13, 2026
Company is currently under Corporate Insolvency Resolution Process (CIRP)
Disclosure made pursuant to Regulation 30 and Para 16(g) of Part A of Schedule III of SEBI LODR
BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR, BSE: 500059)
👀 What to Watch
Investors should exercise extreme caution as equity shareholders typically face significant value erosion or total loss during insolvency proceedings. Monitor the outcomes of CoC meetings for any updates on resolution plans or liquidation orders.
Panacea Biotec Secures INR 20.79 Crore Vaccine Supply Order from CMSS
Panacea Biotec Limited has received a Letter of Award from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, for the supply of Diphtheria and Tetanus (Td) vaccines. The total value of the contract is INR 20.79 Crore. The supply is scheduled to be executed in multiple tranches starting from September/October 2026 and concluding by November/December 2028. This domestic order provides long-term revenue visibility for the company's vaccine segment.
Key Highlights
Total contract value aggregates to INR 20.79 Crore for Td Vaccine supply
Order awarded by Central Medical Services Society (CMSS), a domestic government entity
Execution timeline spans approximately two years from late 2026 to late 2028
The contract involves Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP
👀 What to Watch
Investors should note this as a positive development for revenue stability, though the execution starts in late 2026. Monitor the company's ability to secure similar high-volume government contracts to improve its order book.
Emmbi Industries Short-Term Credit Rating Upgraded to CARE A2
CARE Ratings has upgraded Emmbi Industries' short-term bank facility rating from CARE A3+ to CARE A2, indicating improved liquidity and creditworthiness for short-term obligations. The long-term bank facility rating has been reaffirmed at CARE BBB+ with a Stable outlook. This rating action reflects the company's ability to maintain its financial profile while enhancing its short-term debt servicing capabilities. The upgrade is a positive signal regarding the company's operational efficiency and working capital management.
Key Highlights
Short-term bank facility rating upgraded from CARE A3+ to CARE A2
Long-term bank facility rating reaffirmed at CARE BBB+ with a Stable outlook
The upgrade applies to combined Long Term / Short Term Bank Facilities
Rating action conducted by CARE Ratings Limited as of April 10, 2026
👀 What to Watch
Investors should take this upgrade as a positive sign of improving financial health and liquidity. Monitor the company's interest coverage ratio in upcoming earnings to see if the upgrade leads to lower borrowing costs.
Binani Industries Clarifies Q2 FY25 Discrepancies; Financials Prepared on Liquidation Basis
Binani Industries has responded to NSE's clarification request regarding its Q2 FY25 financial results, citing auditor errors for subsidiary count discrepancies and technical faults for filing delays. The company's financial position is extremely weak, with accumulated losses of ₹21,682 lakhs and a fully eroded net worth. Liabilities exceed total assets by ₹18,543 lakhs, leading auditors to conclude that the 'going concern' assumption is no longer valid. Consequently, the financial statements have been prepared on a liquidation basis, reflecting severe financial distress.
Key Highlights
Accumulated losses reached ₹21,682 lakhs with liabilities exceeding assets by ₹18,543 lakhs as of September 30, 2024.
Auditors stated the 'going concern' assumption is inappropriate and financials are prepared on a liquidation basis.
Outstanding corporate guarantees and letters of comfort total approximately ₹13,196 lakhs for erstwhile subsidiaries.
Reported a standalone net loss of ₹54 lakhs for Q2 FY25 on zero operating income.
Clarified that one subsidiary was struck off in FY 2023-24, leading to previous reporting errors by auditors.
👀 What to Watch
Investors should exercise extreme caution as the company's net worth is fully eroded and it is being valued on a liquidation basis. The significant contingent liabilities and lack of a clear business plan suggest a very high risk of capital loss.
IFB Industries Appoints Sandeep Joseph Abraham as MD & CEO for 5-Year Term
IFB Industries has appointed Mr. Sandeep Joseph Abraham as its new Managing Director and Chief Executive Officer for a five-year term effective April 9, 2026. Mr. Abraham is a seasoned leader with over 30 years of experience, including a significant 11-year tenure as Vice President at MRF and an MBA from IIM Ahmedabad. The company also strengthened its board by appointing Mr. Manoj Kumar Vijay, who has 36 years of experience in finance and legal matters, as an Independent Director for two years. These leadership changes are aimed at driving growth and operational excellence across IFB's diverse business segments.
Key Highlights
Mr. Sandeep Joseph Abraham appointed as MD & CEO for a 5-year tenure starting April 9, 2026
New CEO brings 30+ years of experience and previously managed business operations worth nearly ₹20,000 crore
Mr. Manoj Kumar Vijay appointed as Independent Director for a 2-year term to enhance board governance
Appointments are subject to shareholder approval via General Meeting or Postal Ballot
Mr. Abraham's professional background includes leadership roles at MRF, GSK Consumer Healthcare, and Vodafone
👀 What to Watch
Investors should view this leadership transition positively given Mr. Abraham's extensive experience in scaling large businesses. Monitor upcoming quarterly calls for the new CEO's strategic roadmap for the company's consumer and industrial segments.
IFB Industries Appoints Sandeep Joseph Abraham as MD & CEO and Manoj Kumar Vijay as Director
IFB Industries has announced a major leadership transition with the appointment of Mr. Sandeep Joseph Abraham as Managing Director and CEO for a five-year term starting April 9, 2026. Mr. Abraham is a seasoned professional with over 30 years of experience, including managing business segments worth approximately ₹20,000 Cr at previous roles like MRF. Simultaneously, the company appointed Mr. Manoj Kumar Vijay, who has 36 years of experience in finance and administration, as an Independent Director for two years. These strategic appointments are intended to drive product innovation and operational excellence, subject to shareholder approval.
Key Highlights
Mr. Sandeep Joseph Abraham appointed as MD and CEO for a 5-year term effective April 9, 2026
Mr. Abraham brings 30+ years of experience and previously managed business scales of ₹20,000 Cr
Mr. Manoj Kumar Vijay appointed as Independent Director for a 2-year term starting April 9, 2026
Mr. Vijay has 36 years of experience in finance, legal, and HR within the Usha Martin Group
Both appointments are subject to shareholder approval via General Meeting or Postal Ballot
👀 What to Watch
Investors should view the appointment of a high-caliber CEO from a large-scale background like MRF as a positive signal for future growth. Monitor upcoming quarterly calls for the new CEO's strategic roadmap for the company.
Biocon Receives US FDA Approval for Dapagliflozin Tablets (5 mg and 10 mg)
Biocon Pharma Limited, a subsidiary of Biocon Limited, has received US FDA approval for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The drug is indicated for glycemic control in adults with type 2 diabetes and for reducing heart failure hospitalization risks. This approval strengthens Biocon's integrated diabetes portfolio, which includes oral solids, biosimilar insulin, and GLP-1 peptides. The product will be manufactured at Biocon's existing FDA-approved facilities, ensuring high-quality production standards for the US market.
Key Highlights
Received US FDA approval for Dapagliflozin Tablets in 5 mg and 10 mg dosages.
Indicated for type 2 diabetes treatment and reduction of heart failure hospitalization risk.
Expands Biocon's global diabetes portfolio across oral solids and biosimilars.
Manufacturing to be handled at the company's own FDA-approved facilities.
Strengthens the company's position in the high-value US pharmaceutical market.
👀 What to Watch
Investors should view this as a positive milestone that enhances Biocon's revenue potential in the US generic market. Monitor the commercial launch timeline and the company's ability to capture market share in the SGLT2 inhibitor segment.
A B Infrabuild Secures ₹42.68 Crore Railway Contract for Road Over Bridge Construction
A B Infrabuild Limited has received a Letter of Acceptance from East Coast Railways for the construction of a Road Over Bridge (ROB) between Baruva and Mandasa stations. The contract is valued at approximately ₹42.68 Crore, representing a significant addition to the company's order book. The project involves various engineering components including composite and T-beam girders. The execution period for this domestic contract is set at 24 months, providing revenue visibility for the next two fiscal years.
Key Highlights
Total contract value stands at ₹42,68,20,821.94 awarded by East Coast Railways.
Project involves construction of a Road Over Bridge (ROB) at Railway Km 662/9-11.
The execution timeline for the entire project is 24 months.
The contract is a domestic order with no promoter or related party interest involved.
👀 What to Watch
Investors should track the company's execution progress over the 24-month period and monitor for any further order wins from Indian Railways which could signal a strengthening market position.
IFB Industries Appoints Mr. Arup Das as Executive Director Effective April 2026
IFB Industries has appointed Mr. Arup Das as an Additional Director in the category of Executive Director, effective April 1, 2026. Mr. Das is a company veteran with over 34 years of experience at IFB and a total professional background of 38 years. This appointment is for an interim period until a permanent Chief Executive Officer or Managing Director is appointed. His deep internal knowledge across engineering, marketing, and M&A divisions is expected to provide leadership stability during this transition.
Key Highlights
Appointment of Mr. Arup Das as Executive Director for an interim period starting April 2026.
Mr. Das has been with IFB Industries since 1992, totaling 34 years of internal experience.
He possesses over 38 years of total experience in marketing, sales, and general management.
The role is temporary until the company identifies and appoints a new permanent CEO or Managing Director.
Mr. Das currently serves as the President of M&A and New Projects for the company.
👀 What to Watch
Investors should view this as a move to ensure operational continuity while the company searches for a permanent top executive. Monitor future announcements regarding the permanent CEO/MD appointment for long-term strategic clarity.
Concord Biotech Acquires 100% Stake in Celliimune Biotech for Rs 66 Lakhs
Concord Biotech has completed the 100% acquisition of Celliimune Biotech Private Limited for a cash consideration of Rs 66 lakhs. Celliimune is a biopharmaceutical startup focused on pioneering DNA engineering for cancer therapeutics and cell/gene therapy solutions. While the target entity currently has nil turnover, the acquisition is a strategic move to enter the high-growth oncology research space. This transaction is classified as a related party transaction as the promoter group previously held a majority stake in the target entity.
Key Highlights
Acquisition of 100% equity stake in Celliimune Biotech Private Limited for Rs 66,00,000
Target entity focuses on DNA engineering for cancer therapeutics and cell/gene therapy solutions
Celliimune was incorporated in January 2025 and currently reports nil turnover
Transaction is a related party deal as promoters previously held majority control
Acquisition completed on April 02, 2026, via cash consideration
👀 What to Watch
Investors should view this as a long-term R&D play rather than an immediate revenue driver. Monitor for future updates on clinical breakthroughs or product development from this new subsidiary.
Birla Cable Credit Rating Revised; CE Facilities Downgraded to CARE A (CE) Amid Merger Watch
CARE Ratings has downgraded Birla Cable's credit-enhanced bank facilities totaling ₹296 crore following a downgrade of its guarantor, Vindhya Telelinks Limited (VTL). The downgrade is attributed to VTL's moderate operations, execution delays in its EPC segment, and a stretched operating cycle with debtors rising to ₹2,191.85 crore. However, BCL's standalone rating of ₹55 crore is on 'Positive Watch' due to its proposed merger into VTL, which is expected to streamline operations over the next 10-12 months. BCL's own performance showed revenue growth to ₹557 crore in 9MFY26, though margins slightly compressed to 4.66%.
Key Highlights
Downgraded ₹120 Cr long-term and ₹176 Cr short-term CE facilities to CARE A (CE) and CARE A1 (CE) respectively.
Guarantor Vindhya Telelinks saw debtors increase from ₹1,527.71 Cr in FY25 to ₹2,191.85 Cr as of December 2025.
BCL standalone rating (₹55 Cr) placed on 'Rating Watch with Positive Implications' due to the VTL merger.
Merger swap ratio confirmed at 10 equity shares of VTL for every 115 shares of BCL held.
BCL 9MFY26 revenue rose to ₹557 Cr from ₹505 Cr YoY, but operating margins dipped to 4.66% from 4.93%.
👀 What to Watch
Investors should closely monitor the merger progress with Vindhya Telelinks and the liquidity position of the guarantor, as the downgrade reflects execution challenges in the EPC segment. The positive watch on the standalone rating suggests potential long-term benefits from the amalgamation despite current credit-enhancement downgrades.
